An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors BIND Therapeutics
- 24 Sep 2018 According to an Epic Sciences media release, data from the trial were published in JAMA Oncology 2018.
- 14 Apr 2016 Status changed from active, no longer recruiting to completed.
- 07 Jan 2016 Results from this trial were presented at the 2016 Genitourinary Cancers Symposium, according to a BIND Therapeutics media release.